Therapeutic modulation of prostate cancer metastasis

Sankar N. Krishna, Raymond Bergan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Targeting prostate cancer metastasis has very high therapeutic potential. Prostate cancer is the second most common cause of cancer death among men in the USA, and death results from the development of metastatic disease. In order to metastasize, cancer cells must complete a series of steps that together constitute the metastatic cascade. Each step therefore offers the opportunity for therapeutic targeting. However, practical limitations have served as limiting roadblocks to successfully targeting the metastatic cascade. They include our still-emerging understanding of the underlying biology, as well as the fact that many of the dysregulated processes have critical functionality in otherwise normal cells. We provide a discussion of the underlying biology, as it relates to therapeutic targeting. Therapeutic inroads are rapidly being made, and we present a series of case studies to highlight key points. Finally, future perspectives related to drug discovery for antimetastatic agents are discussed.

Original languageEnglish (US)
Pages (from-to)223-239
Number of pages17
JournalFuture Medicinal Chemistry
Volume6
Issue number2
DOIs
StatePublished - Feb 2014
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Neoplasm Metastasis
Drug Discovery
Therapeutics
Cause of Death
Neoplasms

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Therapeutic modulation of prostate cancer metastasis. / Krishna, Sankar N.; Bergan, Raymond.

In: Future Medicinal Chemistry, Vol. 6, No. 2, 02.2014, p. 223-239.

Research output: Contribution to journalArticle

Krishna, Sankar N. ; Bergan, Raymond. / Therapeutic modulation of prostate cancer metastasis. In: Future Medicinal Chemistry. 2014 ; Vol. 6, No. 2. pp. 223-239.
@article{297e17b50bf84f5588ace20b54acc02e,
title = "Therapeutic modulation of prostate cancer metastasis",
abstract = "Targeting prostate cancer metastasis has very high therapeutic potential. Prostate cancer is the second most common cause of cancer death among men in the USA, and death results from the development of metastatic disease. In order to metastasize, cancer cells must complete a series of steps that together constitute the metastatic cascade. Each step therefore offers the opportunity for therapeutic targeting. However, practical limitations have served as limiting roadblocks to successfully targeting the metastatic cascade. They include our still-emerging understanding of the underlying biology, as well as the fact that many of the dysregulated processes have critical functionality in otherwise normal cells. We provide a discussion of the underlying biology, as it relates to therapeutic targeting. Therapeutic inroads are rapidly being made, and we present a series of case studies to highlight key points. Finally, future perspectives related to drug discovery for antimetastatic agents are discussed.",
author = "Krishna, {Sankar N.} and Raymond Bergan",
year = "2014",
month = "2",
doi = "10.4155/fmc.13.201",
language = "English (US)",
volume = "6",
pages = "223--239",
journal = "Future Medicinal Chemistry",
issn = "1756-8919",
publisher = "Future Science",
number = "2",

}

TY - JOUR

T1 - Therapeutic modulation of prostate cancer metastasis

AU - Krishna, Sankar N.

AU - Bergan, Raymond

PY - 2014/2

Y1 - 2014/2

N2 - Targeting prostate cancer metastasis has very high therapeutic potential. Prostate cancer is the second most common cause of cancer death among men in the USA, and death results from the development of metastatic disease. In order to metastasize, cancer cells must complete a series of steps that together constitute the metastatic cascade. Each step therefore offers the opportunity for therapeutic targeting. However, practical limitations have served as limiting roadblocks to successfully targeting the metastatic cascade. They include our still-emerging understanding of the underlying biology, as well as the fact that many of the dysregulated processes have critical functionality in otherwise normal cells. We provide a discussion of the underlying biology, as it relates to therapeutic targeting. Therapeutic inroads are rapidly being made, and we present a series of case studies to highlight key points. Finally, future perspectives related to drug discovery for antimetastatic agents are discussed.

AB - Targeting prostate cancer metastasis has very high therapeutic potential. Prostate cancer is the second most common cause of cancer death among men in the USA, and death results from the development of metastatic disease. In order to metastasize, cancer cells must complete a series of steps that together constitute the metastatic cascade. Each step therefore offers the opportunity for therapeutic targeting. However, practical limitations have served as limiting roadblocks to successfully targeting the metastatic cascade. They include our still-emerging understanding of the underlying biology, as well as the fact that many of the dysregulated processes have critical functionality in otherwise normal cells. We provide a discussion of the underlying biology, as it relates to therapeutic targeting. Therapeutic inroads are rapidly being made, and we present a series of case studies to highlight key points. Finally, future perspectives related to drug discovery for antimetastatic agents are discussed.

UR - http://www.scopus.com/inward/record.url?scp=84893163282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893163282&partnerID=8YFLogxK

U2 - 10.4155/fmc.13.201

DO - 10.4155/fmc.13.201

M3 - Article

C2 - 24467245

AN - SCOPUS:84893163282

VL - 6

SP - 223

EP - 239

JO - Future Medicinal Chemistry

JF - Future Medicinal Chemistry

SN - 1756-8919

IS - 2

ER -